Plain-English translation of NCT04386967 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new cancer treatment called OH2, which is based on a genetically modified herpes simplex virus that has been engineered to attack cancer cells while also boosting your immune system's ability to fight tumors. Researchers are evaluating whether this medication works safely and effectively on its own, or whether it works better when combined with an existing immunotherapy drug called .
Advanced solid tumors often stop responding to traditional chemotherapy and other standard treatments, leaving patients with limited options. This trial exists to see if a new approach using a modified virus can help patients whose cancers have not responded to or have come back after conventional therapy.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive injections of the medication directly into a tumor lesion. You may receive the medication alone in one group, or combined with injections in another group—both may start on the same day. You will have regular medical visits and imaging scans (CT or MRI) to monitor how your tumors respond and to check for any side effects. The study will track your health and safety closely throughout your participation.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China